Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | CTSL | P07711 | 4/20 | 0.58 |
| ▸ | CCNE1 | P24864 | 4/20 | 0.54 |
| ▸ | CDK2 | P24941 | 4/20 | 0.54 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.54 |
| ▸ | CDK1 | P06493 | 4/20 | 0.53 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.52 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8108586 | 0.89 | TDP1 (0.57) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6947625 | 0.89 | TDP1 (0.57) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6945642 | 0.87 | TDP1 (0.80) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6945307 | 0.85 | TDP1 (0.64) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6820811 | 0.85 | CTSL (0.60) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6942994 | 0.84 | ADORA3 (0.56) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6817715 | 0.84 | CTSL (0.76) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6944125 | 0.83 | ADORA3 (0.68) | TDP1CTSLCCNE1CDK2CDK1 | |
| SCHEMBL6946892 | 0.83 | ADORA2A (0.61) | TDP1CTSLCCNE1CDK2CCNE2 | |
| SCHEMBL6818091 | 0.82 | CTSL (0.75) | CTSLCCNE1CDK2CCNE2CDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612079-B2 | 2,6,9-substituted purine derivatives and their use in the treatment of proliferative disorders | CYCLACEL LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| EP-1399446-B1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LTD (GB) | 2005-08-03 | — | — | EP | disclosed |
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2005-01-13 | — | — | US | disclosed |
| EP-1399446-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF PROLIFERATIVE DISORDERS | Cyclacel Limited (GB) | 2004-03-24 | — | — | EP | disclosed |
| WO-2003002565-A1 | 2,6,9-SUBSTITUTED PURINE DERIVATIVES AND THEIR USE N THE TREATMENT OF PROLIFERATIVE DISORDERS | CYCLACEL LIMITED (GB) | 2003-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050009846-A1 | 2,6,9-Substituted purine derivatives and their use in the treatment of proliferative disorders | TYMP, PNP, IMPDH1 | TDP1 389/4885CTSL 3701/4885CCNE1 390/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.